arrow
R

Rosario García-Vicuña

instituto de investigación sanitaria la princesa (iis-princesa)
H指数:32
被引数:4,354

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Differential Expression of Galectin-1 and Galectin-9 in Immune-Mediated Inflammatory Diseases

免疫介导性炎症疾病中Galectin-1和Galectin-9的差异性表达

2025-09-210
OAAI
Clinical Profiles, Survival, and Lung Function Outcomes in ANCA-Associated Interstitial Lung Disease: An Observational Study

ANCA相关间质性肺疾病的临床特征、生存率和肺功能结局: 一项观察性研究

2025-01-031
OAAI
Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables
2024-09-053
OAAI
PSGL-1, ADAM8, and selectins as potential biomarkers in the diagnostic process of systemic lupus erythematosus and systemic sclerosis: an observational study

PSGL-1,ADAM8和选择素作为系统性红斑狼疮和系统性硬化症诊断过程中的潜在生物标志物: 一项观察性研究

2024-07-190
OAAI
ARE JAKi PLASMA LEVELS RELATED TO CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS?:THE MEASURE STUDY, A MULTICENTRE PROSPECTIVE COHORT STUDY

JAKi血浆水平与类风湿关节炎临床反应是否相关?:MEASURE研究,一项多中心前瞻性队列研究

2024-06-010
PRE
Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis

在类风湿关节炎或银屑病关节炎患者中,甲氨蝶呤暂时中断对SARS-CoV-2疫苗接种后B和T细胞反应的有益作用

2024-01-305
OAAI
Immunoglobulins in systemic sclerosis management. A large multicenter experience
2023-11-0111
PRE
Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
2023-10-237
OAAI
Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis
2023-09-224
OAAI
Relevant SARS-CoV-2 viremia is associated with COVID-19 severity: Prospective cohort study and validation cohort
2022-08-099
OAAI
SARS-CoV-2 Viremia Precedes an IL6 Response in Severe COVID-19 Patients: Results of a Longitudinal Prospective Cohort
2022-06-156
OAAI
Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial
2022-02-234
OAAI